Abstract: Objective: To investigate the effect of intermittent docetaxel combined with endocrine therapy in the treatment of castration-resistant prostate cancer(CRPC) patients.Methods: A total of 102 CRPC patients were selected as the research object, and the selection period was from May 2017 to May 2019. According to the stratified sampling method, they were averagely divided into single-agent 1 group(treated with docetaxel) and single-drug group 2(treated with endocrine therapy) and combined medication group(intermittent docetaxel combined with endocrine therapy). The remission rate was compared among three groups. The serum total prostate specific antigen(tPSA) and free prostate specific antigen(fPSA) expression levels before treatment, 3 and 6 cycles after treatment were evaluated, and the side effects, PFS, and mortality rate were observed.Results: The results of the analysis of the generalized estimation equation showed that:in terms of between groups, repeated measurement results showed that the effective rate of the three groups was compared, and the difference was statistically significant(P<0.05); in terms of time points, the remission rate of patients at different time points was significantly different(P<0.05). Repeated measures analysis of variance showed that there was significant difference among the three groups of tPSA at the time point and between groups(P<0.05), but there was no statistical difference in the interactive comparison(P>0.05); the three groups of fPSA at time point, between groups, and the interaction comparison showed significant difference(P<0.05). The simple effect LSD-t paired comparison showed that before treatment, the difference between the three groups of tPSA and fPSA was not statistically significant(P>0.05); after 3 or 6 cycles of treatment, the tPSA and fPSA of the combination group were lower than those of the single agent 1 Group and single-drug group 2(P<0.01). There was statistically significant difference in the incidence of nausea and vomiting, peripheral neuritis, liver and kidney damage, and bone marrow suppression among the three groups(P<0.05); among them, nausea and vomiting, peripheral neuritis, and bone marrow suppression occurred in the combined drug group were lower than those of single-drug group 1(P<0.05); the incidence of platelet decline, anemia, liver and kidney damage in the combined drug group was lower than that of single-drug group 1, but the difference was not statistically significant(P>0.05); there was no significant difference in the incidence of nausea and vomiting, peripheral neuritis, bone marrow suppression, platelet decline, anemia, liver and kidney function damage, etc. between the combined drug group and the single-drug 2 group(P>0.05); the incidence of nausea and vomiting, peripheral neuritis, bone marrow suppression, thrombocytopenia, anemia, liver and kidney function damage of the single-drug group 2 was lower than that of the single-drug group 1. The PFS of the combination medication group was significantly longer than that of the single-drug group 1 and the single-drug group 2(P<0.05), and the fatality rate was significantly lower than that of the single-drug group 1(P<0.05); the difference was not statistically significant in fatality rate between the combined-drug group and the single-drug group 2(P>0.05).Conclusion: Docetaxel combined with endocrine therapy has a significant effect on the treatment of CRPC, which can better control the development of the disease, and has high safety without serious side effects.